Provided by Tiger Trade Technology Pte. Ltd.

Natera

408.47
-4.8400-1.17%
Pre-market: 408.630.1600+0.04%04:01 EDT
Volume:1.86M
Turnover:772.61M
Market Cap:58.50B
PE:-297.52
High:423.43
Open:413.31
Low:407.37
Close:413.31
52wk High:427.47
52wk Low:157.43
Shares:143.22M
Float Shares:139.00M
Volume Ratio:1.02
T/O Rate:1.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3729
EPS(LYR):-1.5269
ROE:-12.54%
ROA:-8.08%
PB:32.12
PE(LYR):-267.52

Loading ...

Analysts Are Bullish on These Healthcare Stocks: Natera (NTRA), Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Jul 10

Natera Shares Gain 2.8% After EU Certification for Cancer Test

THOMSON REUTERS
·
Jul 09

How New Signatera Colorectal Data and Trial Deals Could Shape Natera’s (NTRA) Long-Term Narrative

Simply Wall St.
·
Jul 09

Natera price target raised to $310 from $250 at Morgan Stanley

TIPRANKS
·
Jul 09

Natera Announces Ivdr Certification for Signatera™ Across Multiple Cancers

THOMSON REUTERS
·
Jul 09

Natera’s Signatera MRD Test Wins EU IVDR Certification for Multiple Cancers

Reuters
·
Jul 09

Natera Executive Chairman Matthew Rabinowitz Reports Disposal of 1,000 Common Shares Worth $280,000

Reuters
·
Jul 09

Natera President, Clinical Diagnostics Solomon Moshkevich Disposes of USD 819,636 in Common Shares

Reuters
·
Jul 07

Natera Announces Board Resignation Amid Governance Transition

TIPRANKS
·
Jul 07

Natera Director Monica Bertagnolli Resigns to Take National Academy of Medicine Role

Reuters
·
Jul 07

Natera is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
Jul 07

Natera Says Colorectal Liver Metastasis Test Identifies Patients Who Benefit From Chemotherapy

MT Newswires Live
·
Jul 06

Natera Signatera MRD Test Data in JAMA Oncology Links Chemo to Overall Survival Gain in Resected Metastatic Colorectal Cancer

Reuters
·
Jul 06

Natera (NTRA) Lands New Trial Partnerships, Is The Upside Already Priced In?

Simply Wall St.
·
Jul 03

When Multi-cancer Blood Screens Could Finally Take Off

Dow Jones
·
Jul 02

Movement Alert|Natera Falls 5.1% in After-Hours Trading, Trading at $270.25

Market Focus
·
Jul 01

Natera is Maintained at Buy by Guggenheim

Dow Jones
·
Jun 29

Natera, Aveta Biomics announce strategic partnership

TIPRANKS
·
Jun 29

Natera Partners with Aveta Biomics on Phase 3 Apg-157 Head and Neck Cancer Trial

Reuters
·
Jun 29

Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of Apg-157 in Head and Neck Cancer

THOMSON REUTERS
·
Jun 29